Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Liabilities (2016 - 2025)

Lipocine (LPCN) has disclosed Total Liabilities for 13 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities rose 22.13% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Sep 2025, up 22.13%, and an annual FY2024 reading of $1.5 million, down 42.51% over the prior year.
  • Total Liabilities was $1.9 million for Q3 2025 at Lipocine, up from $1.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $11.4 million in Q2 2021 and bottomed at $1.3 million in Q1 2025.
  • Average Total Liabilities over 5 years is $3.4 million, with a median of $1.9 million recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 79.85% in 2022, then skyrocketed 37.93% in 2023.
  • Year by year, Total Liabilities stood at $6.9 million in 2021, then tumbled by 72.4% to $1.9 million in 2022, then skyrocketed by 37.93% to $2.6 million in 2023, then plummeted by 42.51% to $1.5 million in 2024, then grew by 27.64% to $1.9 million in 2025.
  • Business Quant data shows Total Liabilities for LPCN at $1.9 million in Q3 2025, $1.4 million in Q2 2025, and $1.3 million in Q1 2025.